Genotech제노텍

Genotech, a small KONEX-listed maker of gene research tools, has no financial statements or news in the data provided, so its current position is hard to judge.

Genotech sells synthetic DNA and gene-based diagnostic kits, plus sequencing and research services, mainly to universities, research institutes, hospitals and biotech firms. Its share price closed at ₩1,199 on 2026-10-16, giving a market value of about ₩6.8B, and it is down 7.4% over one month but up 9.5% over one year. The data does not include annual or trailing financials, so revenue, profit and balance sheet trends cannot be assessed.

What stands out

• The data has no annual or trailing-twelve-month financials and no valuation multiples for the company, so profitability and value cannot be assessed from the pack.
• The share price is ₩1,199, well below its 52-week high of ₩1,600, with a 52-week low listed as ₩0, which looks like a missing or unreliable value.
• Recent filings are routine: an annual report for December 2025, an audit report, an AGM held in March 2026, and investor relations events in May, April, November and October 2025.
• Ownership and flow data show zero foreign ownership and zero net investor flows over 20 days, and no short-selling balance is given.
• The data includes no news headlines, so there is no press coverage to weigh against the filings.

What to watch

• Next periodic financial filings, which would be needed to see revenue, profit and cash position, since none are in the data.
• Any filing on the 5%+ holding report or insider shareholding changes, which were the only ownership-related items listed.
• Trading liquidity and price moves, given the thin data and the sharp one-month decline of 7.4%.